Moderna wins patent lawsuit against BioNTech/Pfizer

Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U.S. Patent Office tribunal that two patents Moderna accused them of infringing were invalid.
Pfizer and BioNTech violated COVID-19 vaccine patent held by Moderna, German court rules
The court said Pfizer and BioNTech would have to provide information on earnings derived from the use of the patent and that they owe Moderna appropriate compensation
Pfizer and BioNTech COVID vaccine broke patent — German court
FRANKFURT - A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make their COVID-19 vaccine.Siding with Moderna, an American pharmaceutical firm that brought the case,
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna. In a statement, the court in the city of Duesseldorf said that Pfizer and BioNTech would have to provide information on earnings derived from the use of the patent and that they owe Moderna appropriate compensation,
Moderna wins patent lawsuit against BioNTech/Pfizer in German court
A German court ruled on Wednesday that BioNTech and Pfizer violated a Covid-19 patent held by rival Moderna. US-based Moderna had asserted claims for information and damages for infringement of its patent rights in the development of the Covid-19 vaccine.
Pfizer could use existing US manufacturing to counter potential tariff hit
By Christy Santhosh (Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its ...
STAT1d
Questions about Pfizer’s GenAI ‘Health Answers’
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...
FiercePharma2d
Pfizer could shift overseas production to US if Trump's pharma tariffs take hold, CEO says
As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert ...
Pfizer Remains A Good Pick For Dividend Investors
Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...
STAT1d
Pharmalittle: We’re reading about Pfizer navigating tariffs, Makary’s pledge to avoid conflicts, and more
Pfizer CEO Albert Bourla said the drugmaker might move overseas manufacturing to its plants in the U.S. as Trump threatens ...
BioSpace1d
Pfizer Prepared to Reshore Manufacturing if Trump Makes Good on Tariff Threats
Eli Lilly also responded to the President's tariff warnings by investing $27 billion to construct four manufacturing ...
Pfizer could use existing U.S. production to counter tariff hit, Reuters reports
Pfizer (PFE) may move overseas manufacturing to its existing plants in the U.S., if required, as the Trump administration threatens numerous ...
Trump Introducing Pfizer CEO Sparks Loud Booing Inside White House
A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...
Managed Healthcare Executive13h
For Pfizer, Some Challengers in ATTR-CM Treatment
Drugs in late-stage development may mean competition on price for two Pfizer medications that, by some accounts, are the most expensive cardiac medications in history.
Hosted on MSN9h
How the 3 New COVID Vaccines Change the Way You Pay
Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and ...